Sleep Therapies for Alzheimer's Disease

Overseen By Leah Harris, BA

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Stanford University

Must not be taking: Sleep medications, Antidepressants

Disqualifiers: Bipolar, Psychosis, Substance abuse, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 6

Duration: 11 weeks

150 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores how sleep problems might affect mood and emotions in people at risk for Alzheimer's Disease. Participants will receive either Cognitive Behavioral Therapy for Insomnia (CBT-I) or Desensitization Therapy for Insomnia (DT-I), a similar active control. The researchers aim to determine if better sleep can help reduce symptoms like anxiety and depression. Individuals who have experienced sleep issues for over three months and have some cognitive problems might find this trial suitable. As an unphased trial, it offers a unique opportunity to contribute to understanding the link between sleep and mood in those at risk for Alzheimer's.

Will I have to stop taking my current medications?

The trial requires that your medications, including any dementia-related ones, be stable for at least 4 weeks before starting. If you are taking medications specifically for sleep disturbances or certain low-dose antidepressants for sleep, you must stop them more than two weeks (for antidepressants) or more than one week (for sleep medications) before the trial begins.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

A previous study found that Desensitization Therapy for Insomnia (DT-I), which reduces stress causing sleep problems, had side effects that most participants could handle. Most did not experience significant negative reactions while using it.

Cognitive Behavioral Therapy for Insomnia (CBT-I) has been extensively studied and is known to improve sleep quality. It employs techniques like limiting time in bed and altering negative thoughts about sleep. Research shows that people using CBT-I often experience better sleep without major side effects.

Overall, both treatments have demonstrated safety with manageable side effects, making them promising options for those with sleep problems and related issues. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about Desensitization Therapy for Insomnia (DT-I) because it offers a novel approach to managing insomnia in Alzheimer's patients by tackling "conditioned arousal," which keeps them awake at night. Unlike standard care options like Cognitive Behavioral Therapy for Insomnia (CBT-I), DT-I uses a unique quasidesensitization method where patients create and practice a personalized hierarchy of activities to decrease nighttime awakenings. This method involves pairing neutral, calming scenes with these activities, helping to recondition the brain's response to waking up at night. By focusing on this specific mechanism, DT-I could provide a significant breakthrough in improving sleep quality for those affected by Alzheimer's.

What evidence suggests that this trial's treatments could be effective for sleep disturbances in Alzheimer's Disease?

Research has shown that Cognitive Behavioral Therapy for Insomnia (CBT-I), one of the treatments studied in this trial, can greatly improve sleep quality. Studies indicate that CBT-I has a moderate to strong positive effect on sleep for people with various health conditions, including Alzheimer's. It works by changing behaviors and thoughts that disrupt sleep. Early research also suggests it may help with thinking skills for those at risk of Alzheimer's.

Desensitization Therapy for Insomnia (DT-I) is another treatment option in this trial, designed to reduce nighttime awakenings. This approach pairs calming activities with bedtime routines to decrease stress that can keep people awake. Although specific data on DT-I is limited, behavioral techniques have been shown to help Alzheimer's patients with sleep issues. ^{1 2 6 7 8}

Who Is on the Research Team?

Andrea Goldstein-Piekarski

Principal Investigator

Stanford University

Are You a Good Fit for This Trial?

This trial is for adults aged 50-90 with sleep disturbances and mild cognitive impairment or early-stage Alzheimer's, experiencing neuropsychiatric symptoms like anxiety or depression. Participants must live near Stanford University, have stable medication use, and a caregiver to assist them. Exclusions include severe mental health risks, substance abuse, certain medical conditions, previous specific therapies for insomnia within the last year, and unvaccinated individuals.

Inclusion Criteria

Fluent and literate in English

Written, informed consent

My medications, including those for dementia, have been the same for the last 4 weeks.

Exclusion Criteria

I have severe issues with my vision, hearing, or hand movement that could prevent me from following the study's requirements.

If you have had serious thoughts about hurting yourself or have made plans to hurt yourself recently, you cannot participate in the study.

I have been diagnosed with bipolar disorder.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either Cognitive Behavioral Therapy for Insomnia (CBT-I) or Desensitization Therapy for Insomnia (DT-I) over 11 weeks

11 weeks

Weekly sessions

Follow-up

Participants are monitored for neuropsychiatric symptoms and sleep disturbances post-treatment

6 months

Assessment at 6 months post-manipulation

What Are the Treatments Tested in This Trial?

Interventions

• Cognitive Behavioral Therapy for Insomnia (CBT-I)
• Desensitization Therapy for insomnia (DT-I)

Trial Overview

The study tests whether treating sleep problems can improve emotional distress in those at risk of or with early Alzheimer's Disease. It involves two treatments: Desensitization Therapy (DT-I) and Cognitive Behavioral Therapy (CBT-I), which includes mindfulness and sleep hygiene education. The effects on brain function related to emotion regulation will be measured using fMRI scans.

How Is the Trial Designed?

Group I: Cognitive Behavioral Therapy for Insomina (CBT-I) Experimental Treatment 1 Intervention

CBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep.

Group II: Desensitization Therapy for Insomnia (DT-I) Active Control 1 Intervention

DT-I is a quasidesensitization treatment presented as a means of eliminating the "conditioned arousal," which prolongs nocturnal awakenings. DT-I has been validated as an active-placebo control condition. Therapists help each DT-I recipient develop a chronological 12-item hierarchy of common activities he/she does on awakening at night (e.g., opening eyes, clock watching). Therapists also help them develop 6 imaginal scenes of themselves engaged in neutral activities (e.g., reading the newspaper). Each session, DT-I recipients are taught to pair neutral scenes with items on the 12-item hierarchy so, by the end of the sixth session, all hierarchy items have been practiced with therapist assistance. Each session, the exercise is tape recorded and the patient is given this tape locked in a player. The patients are told to practice their exercises at home once each day, no less than 2 hours before bedtime, but to avoid using the tape or exercise during sleep periods.

Who Is Running the Clinical Trial?

Stanford University

Lead Sponsor

Trials

2,527

Recruited

17,430,000+

National Institute of Mental Health (NIMH)

Collaborator

Trials

3,007

Recruited

2,852,000+

Published Research Related to This Trial

A systematic review of 38 studies found that most current treatments for sleep disturbances in Alzheimer's dementia are ineffective, highlighting a significant gap in effective interventions.

Among non-pharmacological options, bright light therapy (BLT) showed the best results, while pharmacological treatments were inconsistent and often limited by potential side effects.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Treatment of sleep disturbance in Alzheimer's dementia. Salami, O., Lyketsos, C., Rao, V.[2021]

Insomnia is particularly prevalent in Alzheimer's disease patients, requiring careful diagnosis and management due to its complex causes and potential to worsen disease progression.

While nonpharmacological treatments should be prioritized, pharmacotherapy may be necessary, with options like sedating antidepressants and melatonin being used despite limited high-quality evidence, and newer treatments like dual orexin receptor antagonists showing promise but needing further research.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Impact of Pharmacotherapy on Insomnia in Patients with Alzheimer's Disease. Roland, JP., Bliwise, DL.[2022]

Patients with Alzheimer's disease often experience disrupted sleep, which can lead to nighttime agitation affecting up to 25% of patients, highlighting the need for effective sleep interventions.

While cholinesterase inhibitors may improve REM sleep, they can also cause insomnia; thus, there is a lack of randomized trials on sedative-hypnotics specifically for Alzheimer's patients, suggesting a need for further research into both pharmacologic and nonpharmacologic treatment options.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Sleep disorders in Alzheimer's disease and other dementias. Bliwise, DL.[2022]

Behavioral interventions, including education on sleep hygiene, showed improvements in sleep quantity and efficiency for community-dwelling Alzheimer's disease patients, as evidenced by actigraphic measurements taken over a 2-month period.

One patient maintained sleep improvements at a 6-month follow-up, highlighting the potential long-term benefits of these behavioral strategies in managing sleep disturbances in dementia.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Treatment of sleep and nighttime disturbances in Alzheimer's disease: a behavior management approach. McCurry, SM., Logsdon, RG., Vitiello, MV., et al.[2007]

Intensive sleep re-training, a new therapy for chronic insomnia, shows rapid improvements in sleep and daytime functioning, comparable to traditional stimulus control therapy, but completed in just 24 hours during sleep deprivation.

Advancements in smartphone technology now allow this therapy to be more accessible to patients by using behavioral responses to measure sleep/wake states, rather than relying on complex EEG monitoring.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Intensive Sleep Re-Training: From Bench to Bedside. Lack, L., Scott, H., Micic, G., et al.[2020]

The NITE-AD sleep education program significantly improved sleep quality in Alzheimer's disease patients, leading to fewer nighttime awakenings and reduced depression, as evidenced by a randomized controlled trial with 36 participants over 6 months.

Patients in the NITE-AD program maintained their sleep improvements and showed lower daytime sleepiness compared to control subjects, highlighting the effectiveness of behavioral techniques like sleep hygiene education and increased light exposure.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Nighttime insomnia treatment and education for Alzheimer's disease: a randomized, controlled trial. McCurry, SM., Gibbons, LE., Logsdon, RG., et al.[2022]

In a study with 20 subjects, targeting both presleep tension and intrusive cognitions led to a greater reduction in the time it took to fall asleep and daytime impairment compared to focusing on presleep tension alone.

Modifying individuals' perceptions of sleep did not provide additional benefits over treating presleep tension, suggesting that addressing both tension and intrusive thoughts is more effective for improving sleep onset.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Behavioral treatment of presleep tension and intrusive cognitions in patients with severe predormital insomnia. Mitchell, KR.[2019]

In a clinical trial involving 157 participants with Alzheimer's disease, melatonin did not show significant improvements in objective sleep measures compared to placebo, indicating it may not be an effective treatment for insomnia in this population.

However, there were some nonsignificant trends suggesting potential benefits, particularly with the 2.5-mg slow-release formulation, which showed improvements in caregiver-reported sleep quality without increasing adverse events, suggesting it may be safe for use.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Singer, C., Tractenberg, RE., Kaye, J., et al.[2019]

Intensive Sleep Retraining is a promising behavioral treatment for sleep onset insomnia that can significantly improve symptoms after just one session.

Recent advancements in technology allow this technique to be self-administered at home, potentially enhancing its accessibility and effectiveness as a complementary approach to cognitive-behavioral therapy for insomnia.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Wearable Device-Delivered Intensive Sleep Retraining as an Adjunctive Treatment to Kickstart Cognitive-Behavioral Therapy for Insomnia. Bensen-Boakes, DB., Murali, T., Lovato, N., et al.[2023]

Many patients with Alzheimer's disease experience significant sleep disruptions, which may not only be a symptom of the disease but could also contribute to its progression.

Research suggests that addressing these sleep disturbances could potentially target underlying mechanisms of Alzheimer's, indicating that effective sleep interventions might help modify the disease course, although further large-scale studies are needed to confirm this.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Sleep and its regulation: An emerging pathogenic and treatment frontier in Alzheimer's disease. Kent, BA., Feldman, HH., Nygaard, HB.[2022]

The DREAMS-START program, a non-pharmacological therapy for sleep disturbances in dementia, was found to be feasible and acceptable, with 66% of eligible participants consenting to the study and 88% adhering to the intervention.

This study indicates that a structured approach to addressing sleep issues in dementia, involving family carers and evidence-based strategies, can be effectively implemented, which is crucial given the lack of effective treatments for sleep disturbances in this population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

DREAMS-START (Dementia RElAted Manual for Sleep; STrAtegies for RelaTives) for people with dementia and sleep disturbances: a single-blind feasibility and acceptability randomized controlled trial. Livingston, G., Barber, JA., Kinnunen, KM., et al.[2021]

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC8157102/

Cognitive behavioral therapy for insomnia to enhance ...

CBT-I has been shown to have a medium to large effect on sleep outcomes in people with a variety of comorbid medical or psychiatric conditions [12,14] and is ...

2.

sciencedirect.com

sciencedirect.com/science/article/abs/pii/S1551714420302688

Cognitive behavioral therapy for insomnia to enhance ...

The objective of the proposed study is to examine the efficacy of CBT-I on improving cognitive function in older adults with symptoms of insomnia.

3.

frontiersin.org

frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2025.1700496/full

Cognitive Behavioral Therapy for Insomnia in ...

Early signals suggested potential cognitive benefits in prodromal populations (AD/MCI), 27 and exploratory observations linked improved sleep ...

4.

bmchealthservres.biomedcentral.com

bmchealthservres.biomedcentral.com/articles/10.1186/s12913-022-07619-w

Costs associated with treatment of insomnia in Alzheimer's ...

The Caregiver Sleep Research study is evaluating whether mindfulness meditation is non-inferior to cognitive behavioral therapy for insomnia (CBT-I)

5.

researchgate.net

researchgate.net/publication/343148822_Cognitive-Behavioral_Therapy_for_Insomnia_CBT-I

Cognitive-Behavioral Therapy for Insomnia (CBT-I)

Alzheimer's disease and insomnia: a bibliometric study and visualization analysis ... Results showed that eCBT-I improved insomnia severity, sleep efficiency ...

6.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC12425456/

Associations of chronic insomnia, longitudinal cognitive ...

We found an association between insomnia, cognitive decline, and increased risk for CI. Insomnia with reduced sleep was associated with worse ...

7.

sciencedirect.com

sciencedirect.com/science/article/pii/S138994572500156X

Effectiveness of group-delivered cognitive behavioural ...

Results from a meta-analysis showed that group-delivered CBT-I led to improved sleep quality and better sleep, especially regarding sleep onset latency, sleep ...

8.

neurology.org

neurology.org/doi/10.1212/WNL.0000000000214155

Associations of Chronic Insomnia, Longitudinal Cognitive ...

Despite growing evidence linking insomnia to incident dementia, underlying pathologic changes contributing to cognitive decline remain unclear.